New Launch18 Oct 2025, 10:54 am
Gujarat Themis Biosyn Ltd Completes Expansion of Fermentation Block, Commences Commercial Production
AI Summary
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Gujarat Themis Biosyn Ltd has announced the completion of the expansion of its Fermentation Block at its manufacturing facilities in Vapi, Gujarat. The first batch of commercial production of Rifamycin-S and Rifamycin-O has commenced on Saturday, October 18, 2025. This expansion has increased the company's overall fermentation capacity from 450 KL to 990 KL, further strengthening its manufacturing capabilities to produce multiple fermentation products. This capacity expansion positions the company to capitalise on the significant growth opportunities in the fermentation segment.
Key Highlights
- Gujarat Themis Biosyn Ltd has completed the expansion of its Fermentation Block at its Vapi, Gujarat facilities.
- The first batch of commercial production of Rifamycin-S and Rifamycin-O has commenced.
- The expansion has increased the company's overall fermentation capacity from 450 KL to 990 KL.
- This capacity expansion strengthens the company's manufacturing capabilities to produce multiple fermentation products.
- The company is now in a strong position to capitalise on the significant growth opportunities in the fermentation segment.